Claritas HealthTech begins validation of AI tool for bladder cancer detection

KUALA LUMPUR, Dec 1 (Bernama) – Claritas HealthTech (Claritas), which specialises in medical image enhancement and artificial intelligence-assisted diagnostic tools, has started clinical validation of a software which it had jointly developed via a research collaboration with Singapore’s Khoo Teck Puat Hospital.

Known as CystoSmart, the medical device is an image enhancement and AI diagnostic tool for bladder cancer detection in images (videos and camera stream) seen on white light cystoscopy and narrow-band imaging cystoscopy, a statement said.

The device was developed under the leadership of consultant urologist Dr Yeow SiYing who said their aim was to develop an AI diagnostic adjunct that enhances the accuracy of bladder cancer detection.

“This will be beneficial in allowing appropriate treatment for newly diagnosed cancers, accurate recognition of tumour recurrences and complete tumour resection during surgery,” Dr Yeow said.

Claritas chief clinical strategy officer Dr Arup Paul highlighted the challenges of developing AI tools for cystoscopy that work in real-life scenarios.

“We are confident of moving into the next stage, with clinical evaluations utilising CystoSmart to demonstrate benefits for patients, clinicians, and healthcare systems,” he said.

Bladder cancer is the 10th most common cancer worldwide and the sixth most common in men. It is known to have high recurrence rates and significant risks of disease progression.

Early detection of bladder cancers and recognition of disease recurrence can substantially reduce patient morbidity and healthcare costs, reduce the risks of disease progression, and improve overall survival.

This collaboration was facilitated by the National Healthcare Group’s (NHG) Centre for Medical Technologies and Innovations. NHG is one of the largest regional health systems in Singapore.

-- BERNAMA